LogicBio Therapeutics

96 articles about LogicBio Therapeutics

• LogicBio Therapeutics Reports First Quarter Year 2021 Financial Results and Provides Business Update

  5/10/2021

  - First patient for Phase 1/2 SUNRISE trial expected to be enrolled by mid-year 2021 - Business Development Deals signed with Daichi-Sankyo and CANbridge Pharmaceuticals - New members recently added to Leadership Team

• LogicBio Therapeutics Strengthens Management Team with Key Appointments

  5/10/2021

  New leadership includes Andrea Paul as general counsel and corporate secretary, and Janice Olson as senior vice president, strategy and portfolio management, bringing extensive experience in gene therapy and rare disease

• LogicBio Announces Presentations at Upcoming American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

  5/4/2021

  LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare and serious diseases from infancy through adulthood, today announced several preclinical data presentations, including an oral presentation, will be delivered at the 24th Annual American Society of Gene and Cell Therapy (ASGCT) Virtual Meeting

• LogicBio Announces Presentation of Retrospective Study of Disease Course in Pediatric Patients with Severe Methylmalonic Acidemia

  5/3/2021

  LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare and serious diseases from infancy through adulthood, today announced results from a retrospective study of the disease course in pediatric patients living with severe methylmalonic acidemia

• LogicBio Therapeutics Announces Strategic Collaboration and Option Agreement with CANbridge Pharmaceuticals Leveraging Gene Editing and Gene Delivery Platforms

  4/27/2021

  - LogicBio grants exclusive option to license LB-001 in Greater China; investigational treatment for methylmalonic acidemia based on GeneRide™ platform - Deal also grants worldwide license for AAV sL65, the first capsid based on LogicBio proprietary sAAVyTM platform, to support development of CANbridge gene therapy programs for Fabry disease, Pompe disease and options for two additional indications

• LogicBio Therapeutics Announces Research Collaboration with Daiichi Sankyo

  4/27/2021

  - Under the terms of the research collaboration and exclusive option agreement, the companies will initiate a gene editing research program dedicated to the treatment of two early onset indications with high unmet need, leveraging the GeneRide™ platform -

• LogicBio Therapeutics Announces Clinical and Corporate Updates

  4/27/2021

  - First patient for Phase I/II SUNRISE trial expected to be enrolled by mid-year 2021 - Company also entered into strategic collaboration with CANbridge Pharmaceuticals and research partnership with Daiichi Sankyo

• CANbridge Pharmaceuticals Announces Strategic Collaboration with LogicBio Therapeutics and Licenses to Gene Delivery and Editing Platforms

  4/27/2021

  Worldwide License to AAV sL65 Capsid, Novel Liver-Targeting Capsid, to Support Development of CANbridge Gene Therapy Programs for Fabry disease, Pompe disease and Options for two Additional Indications Option to Exclusive License for LB-001, Investigational Gene Editing Treatment for Methylmalonic Acidemia, in Greater China

• LogicBio Therapeutics to Present at 2021 Redburn Gene Therapy Summit

  3/30/2021

  LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company pioneering gene delivery and gene editing platforms to address rare and serious diseases from infancy through adulthood, today announced that chief executive officer Frederic Chereau will be participating on a panel at the 2021 Redburn Gene Therapy Summit.

• LogicBio Therapeutics Reports Full Year 2020 Financial Results and Provides Business Update

  3/15/2021

  - First patient for Phase 1/2 SUNRISE trial expected to be enrolled in early 2021 -Translational preclinical data for sAAVy platform shows substantial improvements over liver tropic capsids used in gene therapy programs to date -New Chief Scientific and Chief Financial Officers recently added to Executive Team

• LogicBio Announces Extension Of Collaboration With Children's Medical Research Institute

  1/7/2021

  Collaboration seeks to develop next-generation viral vectors for gene therapy and gene editing applications in liver and two other tissues. Program brings new levels of momentum to LogicBio as company plans for initiation of enrollment of SUNRISE Phase I/II clinical trial in treatment of methylmalonic acidemia (MMA) and other milestones.

• LogicBio Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference

  1/6/2021

   LogicBio Therapeutics, Inc. (Nasdaq: LOGC), a clinical stage genetic medicines company, today announced that president and chief executive officer Fred Chereau will present virtually at the 39 th Annual J.P. Morgan Healthcare Conference on Thursday, January 14, 2021 at 4:30 pm ET . Mr. Chereau will provide an overview of com

• Cecilia Jones Joins LogicBio Therapeutics as Chief Financial Officer

  12/22/2020

  LogicBio Therapeutics, Inc. (Nasdaq: LOGC), a clinical stage genetic medicines company, today announced the appointment of Cecilia Jones as the Company's chief financial officer, effective January 11, 2021.

• 

  BioSpace Movers & Shakers, Dec. 18

  12/18/2020

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• LogicBio Therapeutics names Daphne Karydas and Jeff Goater to Board of Directors

  12/14/2020

   LogicBio Therapeutics, Inc. (Nasdaq: LOGC), a clinical stage genetic medicines company developing therapies based on advanced gene editing technology and next-generation synthetic capsids, today announced that Daphne Karydas and Jeff Goater have been appointed to the Company's board of directors. 

• LogicBio Therapeutics to Present at Upcoming Investor Conferences - Nov 12, 2020

  11/12/2020

  LogicBio Therapeutics, Inc., a company dedicated to extending the reach of genetic medicine with pioneering targeted delivery announced senior member of management will be presenting at upcoming investor conferences

• LogicBio Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update

  11/9/2020

  IND for LB-001 in methylmalonic acidemia (MMA)cleared in August 2020, with first patient in Phase 1/2 SUNRISE trial expected to be enrolled in early 2021

• LogicBio Therapeutics Receives FDA Fast Track Designation for LB-001 for the Treatment of Methylmalonic Acidemia (MMA)

  11/4/2020

  LogicBio Therapeutics, Inc. (Nasdaq:LOGC) (LogicBio), a company dedicated to extending the reach of genetic medicine with pioneering targeted delivery platforms, announced today the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to its clinical candidate, LB-001 for the treatment methylmalonic acidemia (MMA). According to the FDA, the purpose of Fast Track designation is to get important new drugs to patients earli

• 

  FDA Awards Fast Track Designation to Multiple Non-COVID-19 Candidates

  11/4/2020

  While the world has largely been focused on the development of vaccines and therapeutics for COVID-19, the U.S. FDA has remained busy lining up potential approvals of medications for other diseases and illnesses.

• LogicBio Therapeutics Announces Appointment of Veteran Biotech Executive Mariana Nacht, Ph.D., as Chief Scientific Officer and Kyle Chiang, Ph.D., Promoted to Chief Operating Officer

  11/3/2020

  LogicBio Therapeutics, Inc. (Nasdaq:LOGC) (LogicBio), a company dedicated to extending the reach of genetic medicine with pioneering targeted delivery platforms, today announced the appointment of Mariana Nacht, Ph.D., as chief scientific officer, effective Nov. 30, 2020, and the promotion of Kyle Chiang, Ph.D., to chief operating officer, effective Nov. 2, 2020.